Trial Profile
A Phase I, Open-label, Dose-escalation Study of Apatinib in Combination With Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions
- 01 Feb 2019 Results assessing the maximum tolerated dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients, published in the Investigational New Drugs.
- 01 Feb 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Preliminary results (n=9) presented at the 54th Annual Meeting of the American Society of Clinical Oncology